65,437 trials
Chronic Obstructive Pulmonary Disease
Primary: Pre-dose Forced Expiratory Volume in One Second (FEV1) — 104.6; 101.5 percentage of Baseline
Hypertension
Primary: Blood Pressure — -10.1; -9.1 mm Hg — p=0.50
Schizophrenia · Psychotic Disorders · Substance Abuse
Primary: Change Over Time in Frequency of Heavy Drinking Days (Used to Evaluate Treatment Efficacy) — -.11; .68 heavy drinking days per week — p=0.054
Colorectal Cancer
Primary: Progression Free Survival — 5.8; 7.2; 7.8 Months
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Endpoint (Week 26) — -1.11; -0.68 percentage of total hemoglobin — p=<.001
Bacterial Infections · Intra-Abdominal Infection · Pneumonia, Bacterial
Primary: Maximum Observed Plasma Concentration (Cmax) — 456; 1515; 2599 ng/mL
Healthy
Primary: Percentage of Participants With a 50 Percent (%) or More Reduction in Sperm Concentration From Baseline (Bsl) to End of Study (EOS) — 9.2; 3.2 percentage of participants
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Pancreatic Cancer · Bile Duct Cancer
Primary: Postoperative Infectious Complication — 7; 15 participants — p=<0.05
Schizophrenia
Primary: Assessment of Negative Symptoms and Neuroleptic Induced Deficit Syndromes by Objective Rating Scales — -1.30; -0.28; -0.66; -0.70 units on a scale
Inflammatory Bowel Disease · Uterine Cervical Dysplasia
Primary: Twelve Month Antibody Response to the Human Papillomavirus (HPV) Vaccine (Geometric Mean Titers [GMT]) — 120.5; 175.0; 861.0; 68.9 mMU/mL
Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months — 7.80; 0.63; 0.32; 1.63 percentage change in BMD — p=<0.001
Osteoporosis, Postmenopausal
Primary: Part A - Cumulative Skin Irritation by Draize Score — 299; 40; 146; 390 patches with Draize scores
Arrhythmia
Primary: Left Atrial Effective Refractory Period — 2.5; 5; 2.5; 10.8 msec
Diabetes Mellitus
Primary: Change Score for "HbA1c <9 Percent" — 0.01; 0.02; 0.04 units on a scale — p=0.307